The expansion helps CIS display platform for the discovery of biological therapeutics, diagnostics and reagents using Tecan liquid handling robots and screening equipment. The development further brings additional
The results of the trial suggested that Adva-27 is 16-times more effective at killing Multidrug Resistant Breast Cancer cells in comparison to Etoposide. Additionally, the data from the
After the transaction, Global Pharm obtained the new business license for Bozhou Xinghe, with registered capital of $3.1m. Under the terms of this acquisition, Global Pharm will pay
The products are based on the hormones ethinylestradiol (estrogen) and drospirenone. The EPO’s decision was backed by an appeal from Hexal (Sandoz) which was filed in 2006 against
Caduet Combination Tablets are oral combination drug of Norbasc Tablets and Lipitor Tablets. Under the agreement, Pfizer is responsible to seek marketing approval for the product in Japan,
The company said the decision is still subject to the approval of board members. Most recently, Kress worked as the vice president and general manager for Gilead France
AMT has developed Glybera for the treatment of patients who are suffering from genetic disorder lipoprotein lipase deficiency (LPLD). The re-examination of the dossier is expected to be
SAFC provides raw materials and process development services to establish the CHOZN series of cell lines to build therapeutic protein and monoclonal antibody manufacturing platform. SAFC Cell Sciences
Currently, he is serving as the executive VP of Business Development of the company and joined the subsidiary of Kyowa Hakko Kirin (KHK), ProStrakan in 1997. Stratford said
Palonosetron (palonosetron hydrochloride) is a second generation 5-HT3 Receptor Antagonist, developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer. Longo said in their
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.